Express Press Release Distribution

Accounting
Advertising
Aerospace
Agriculture
Apparel & Fashion
Automotive
Biotech
Chemicals
Computers
Construction
Consumer Services
Defense
Education
Electronics
Energy
Entertainment
Environment
Financial
Food & Beverage
Government
Healthcare
Human Resources
Industrial
International Trade
Internet & Online
Law
Management
Marketing
Media
Non Profit
Pharmaceuticals
Real Estate
Retail
Semiconductors
Small Business
Software
Sports
Telecommunications
Transportation / Logistics
Travel

EPR Archived News

Archived News 2012
~ April
~ March
~ February
~ January

Archived News 2011
~ December
~ November
~ October
~ September
~ August
~ July
~ June
~ May
~ April
~ March
~ February
~ January

Archived News 2010
Archived News 2009
Archived News 2008
Archived News 2007
Archived News 2006
Archived News 2005
Archived News 2004

 

Insulin Manufacturing in India - Opportunities Pouring In

Released on = June 27, 2006, 9:52 pm

Press Release Author = RNCOS

Industry = Pharmaceuticals

Press Release Summary = With growing opportunities for insulin manufacturing many
key players are all set to jump in the marketplace.

Press Release Body = Followed by China, India is the second country in the number of
diabetics worldwide. There’re about 30Mn patients of diabetes in India at present,
whereas this number is expected to cross 50Mn towards the year 2025.

With leading pharmaceutical majors such as Ranbaxy, Nicholas Piramal, Cipla, Bharat
Biotech and Shantha Biotech exploring the possibilities that exist in this sector,
the insulin segment in India is heading towards a price war. While Nicholas Piramal
is all set to enter the insulin sensitiser segment, the other players including
Ranbaxy, Shantha Biotech and Cipla, will make it to the human insulin segment.

Studying the opportunities that exist in this market Levemir, a type of basal
insulin, was launched by Novo Nordisk India.

As per a recent market research report named “New Developments in Insulin Delivery
Systems (2006)”, published by RNCOS, “Growing at an annual rate of 22%, the present
value of Insulin market in India is calculated to be around Rs. 3Bn. At present,
Levemir (the long acting insulin) is accountable for 10% of the 3.5Bn insulin market
in India. It’s expected to take over ¼th of basal insulin market in India till March
2007”.

Reports Highlights

§ Analysis of the current market trends.
§ Comprehensive discussion about the leading edge technologies.
§ Scope of the main insulin delivery systems worldwide.
§ Market projections for the insulin delivery systems
§ Profile discussion of key players in this sector.
§ Overview of various opportunities & challenges in front of the industry.
§ Classification of various actors stimulating the industry.

About RNCOS:
RNCOS, incorporated in 2002, provides Market Research Reports for your business
needs and aims to put an end to your information pursuit. Our expertise in gathering
global business information for industry research, corporate training, growth
consulting, and business consulting, brings reputed companies and firms to us for
business enhancement solutions. We can be your one-stop-shop for Industry research
information and niche market analysis.

To purchase your copy: http://www.rncos.com/Report/IM040.htm
For more information about the report please visit www.rncos.com


Web Site = http://www.rncos.com

Contact Details = RNCOS
Shushmul Maheshwari
Head of Business Development
29, 1st Floor, Patparganj Industrial area, Delhi 92
91-11-4214-1229
info@rncos.com

  • Printer Friendly Format
  • Back to previous page...
  • Back to home page...
  • Submit your press releases...
  •